Home/Pipeline/Orion Collaboration Program 3

Orion Collaboration Program 3

Oncology (undisclosed)

Research/PreclinicalActive

Key Facts

Indication

Oncology (undisclosed)

Phase

Research/Preclinical

Status

Active

Company

Glykos Finland

About Glykos Finland

Glykos is a Finnish biotech company specializing in next-generation antibody-drug conjugates (ADCs) for oncology. Its core innovation is a proprietary platform featuring hydrophilic linkers and novel payloads (including auristatin, anthracyclin, and exatecan classes) designed to significantly widen the therapeutic window. The company is in late preclinical development with a lead candidate targeting CD33 for AML and MM, and has secured a major collaboration with Orion Corporation, signaling strong validation of its technology. Glykos operates as a private, preclinical-stage firm combining internal pipeline development with platform licensing and service offerings.

View full company profile

Therapeutic Areas

Oncology

Other Oncology (undisclosed) Drugs

Drug	Company	Phase	Status
CLD-601	Calidi Biotherapeutics	Discovery	Active
Protease Inhibitor Discovery Programs	Medivir	Discovery	Active
Nucleoside/Nucleotide Discovery Programs	Medivir	Discovery	Active
Orion Collaboration Program 1	Glykos Finland	Research/Preclinical	Active
Orion Collaboration Program 2	Glykos Finland	Research/Preclinical	Active
Orion Collaboration Program 4-6 (Extended)	Glykos Finland	Research	Active
NEX-20	Nanexa	Preclinical	Active
NEX-18	Nanexa	Preclinical	Active
E7386	PRISM Biolabs	Phase 1	Active (Co-created with Eisai, clinical results published)
ISB 830	Glenmark Pharmaceuticals	Preclinical	Active
TEM-1	Tempus AI	Discovery/Preclinical	Active
TEM-2	Tempus AI	Discovery/Preclinical	Active